- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
Central Retinal Vein Occlusion Market was valued at USD 3.4 billion in 2022 and is poised to grow at a CAGR of 6.2% over 2023-2029. Central retinal vein occlusion (CRVO) is a condition in which the main vein that drains blood from the retina closes off partially or completely at or proximal to the lamina cribrosa of the optic nerve, where the central vein exists in the eye, causing blurred vision, and other eye problems. Based on the treatment type, Anti–vascular endothelial growth factor is anticipated to dominate the central retinal vein occlusion market share over the forecast period. According to a research report, globally, an estimated 2.5 million adults are affected by central retinal vein occlusion. The rise of ophthalmic disease with the increase in the elderly population will act as the central retinal vein occlusion market growth driver, whereas the high cost of treatment and side effects would be the restraining factor for the market. Investment by the market players in the treatment and diagnosis of the condition and in product development and expansion of product portfolios are opportunities for the expansion of the market.
Fastest Growing Market
The increasing prevalence of diabetes and atherosclerosis and rising cases of patients with myeloma, lymphoma, and glaucoma are the major factors accelerating the growth of the central retinal vein occlusion market. Furthermore, there are emerging therapies including ONS-5010, KSI-301, Vabysmo, and others for retinal vein occlusion with the potential to create a positive shift in the market. Thus, the increased awareness, research, and development for eye disorders will lead to market growth within the forecast period.
The Central Retinal Vein Occlusion market was valued at USD 3.4 million in 2022 and is expected to grow at a 6.2% CAGR over the forecast period 2023 – 2029.
Investment by the market players in the treatment and diagnosis of the condition and in product development and expansion of product portfolios are the key opportunities for the Central Retinal Vein Occlusion market.
The rise of ophthalmic disease with the increase in elderly population are the growth drivers in the Central Retinal Vein Occlusion market.
Allergan, Bayer AG, IRIDEX Corporation, Lumenis, Novartis AG, NIDEK CO., LTD., Roche Ltd., Regeneron Pharmaceuticals, Inc., Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, and Amgen Inc. are a few companies operating in the Central Retinal Vein Occlusion market.